The online home for the primary care professionals managing patients with cardiovascular disease, diabetes and related diseases.

Monday, 21 November 2016
HF has a major impact on patients, their families, the NHS and social care services. It still has a poor prognosis, worse than many of the common cancers that also affect older people. It causes significant morbidity and imposes a major cost burden on the health service. This editorial provides an introduction to a special supplement on a first-in-class oral treatment for heart failure.
Category: Editorial
Topics covered:
Thursday, 27 October 2016
Targeting cardiovascular disease risk factors may be important across a person’s lifetime, as a new study from the US National Institutes of Health shows that efforts to prevent risk factors should extend to those over 65 years of age.
Topics covered:
Thursday, 27 October 2016
Semaglutide, an investigational human glucagon-like peptide-1 (GLP-1) analogue, significantly reduced the risk of the primary composite endpoint of time to first occurrence of cardiovascular (CV) death, non-fatal myocardial infarction or non-fatal stroke by 26% vs placebo, when added to standard of care in adults with type 2 diabetes at high CV risk.
Topics covered:
Thursday, 27 October 2016
The benefits of statin therapy have been repeatedly underestimated, and the harms exaggerated, due to misinterpretation of the evidence, according to the authors of a major review published in The Lancet recently.
Monday, 24 October 2016
Commissioning is not so different from seeing patients. As a GP you listen, examine, draw up a diagnosis and plan treatment. In commissioning, the community served by the clinical commissioning group (CCG) is the ‘patient’. When considering the introduction of a new treatment for heart failure (HF) such as sacubitril/valsartan (Entresto), we must consider not only its acquisition costs but also its potential benefits in improving patients' symptoms and reducing expensive hospital admissions.
Category: Editorial
Topics covered:
Friday, 21 October 2016
Sacubitril/valsartan (Entresto), the first angiotensin receptor-neprilysin inhibitor (ARNI), is a recently licensed medication that has been shown to improve outcomes for patients with symptomatic chronic HF with reduced ejection fraction (HF-REF) compared with current gold-standard treatment with an ACE inhibitor. This article describes the pharmacist’s role in supporting patients receiving sacubitril/valsartan.
Category: Editorial
Topics covered:
Friday, 21 October 2016
Many patients with heart failure rely on practice nurses to monitor their care. A multidisciplinary team (MDT) integrated community approach has been endorsed by NICE guidelines when delivering HF care. This article provides practice nurses with the information they need to understand the condition, current treatment guidelines, and the new treatment – sacubitril/valsartan, the first-in-class angiotensin receptor-neprilysin inhibitor.
Category: Editorial
Topics covered:
Friday, 21 October 2016
A number of drug classes are used in the treatment of patients with heart failure. This illustrated Back to Basics poster describes the various drugs and their mechanisms of action to give health care professionals and their patients a greater understanding of heart failure management and where sacubitril/valsartan fits into the picture.
Category: Back to Basics
Topics covered:
Friday, 21 October 2016
This article describes the use of sacubitril/valsartan – the first-in-class angiotensin receptor-neprilysin inhibitor (ARNI) in primary care and how the new drug fits in the heart failure treatment pathway. Current guidelines and case studies are also explored to provide further understanding of this latest HF treatment to enter clinical use.
Category: Editorial
Topics covered:
Friday, 21 October 2016
This article gives an overview of sacubitril/valsartan (Entresto), a first-in-class angiotensin receptor-neprilysin inhibitor comprising valsartan, an angiotensin II receptor blocker and the neprilysin inhibitor sacubitril. The drug has been approved for the treatment of symptomatic (NYHA class (II-IV) chronic heart failure and reduced ejection fraction (HF-REF) in adults.
Category: Editorial
Topics covered:

Article search and filter